Story perspectives

GSK Acquires 35Pharma for $950M, Expands Pipeline Rapidly

2/25/2026

Summary

Story summary

GlaxoSmithKline plc (GSK) finalized a $950 million acquisition of Canadian biotech 35Pharma, signaling a rapid pipeline expansion under new CEO Luke Miels.
HS235 is an experimental pulmonary hypertension treatment in Phase 1 that aims to reduce bleeding risks and contrasts with Merck's Winrevair.
GSK seeks rapid pipeline growth through acquisitions to address investor concerns over patent expirations.
GSK also licensed two siRNA therapeutics from Frontier Biotechnologies, diversifying its portfolio.

1 of 1

Story summary

GlaxoSmithKline plc (GSK) finalized a $950 million acquisition of Canadian biotech 35Pharma, signaling a rapid pipeline expansion under new CEO Luke Miels.
HS235 is an experimental pulmonary hypertension treatment in Phase 1 that aims to reduce bleeding risks and contrasts with Merck's Winrevair.
GSK seeks rapid pipeline growth through acquisitions to address investor concerns over patent expirations.
GSK also licensed two siRNA therapeutics from Frontier Biotechnologies, diversifying its portfolio.